Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia
NCT07257640Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Nov 2025
- Primary completion
- Nov 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of interleukin-5 chimeric antigen receptor T cells in chronic eosinophilic leukemia (CEL), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Started Nov 2025; status: recruiting.
02
Drugs
interleukin-5 chimeric antigen receptor T cells
03
Conditions
chronic eosinophilic leukemia (CEL)
Beyond the preview
Go deeper on NCT07257640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07257640.